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Zoltán Vokó1,2,3*, László Nagyjánosi2 and Zoltán Kaló1,2Abstract
Background: The cervical cancer screening program implemented in Hungary to date has not been successful.
Along with screening, vaccination is an effective intervention to prevent cervical cancer. The aim of this study was
to assess the cost-effectiveness of adding vaccination with the human papillomavirus 16/18 vaccine to the current
cervical cancer screening program in Hungary.
Methods: We developed a cohort simulation state-transition Markov model to model the life course of 12-year-old
girls. Eighty percent participation in the HPV vaccination program at 12 years of age was assumed. Transitional
probabilities were estimated using data from the literature. Local data were used regarding screening participation
rates, and the costs were estimated in US $. We applied the purchasing power parity exchange rate of 129 HUF/$
to the cost data. Only direct health care costs were considered. We used a 3.7% discount rate for both the cost and
quality-adjusted life years (QALYs). The time horizon was 88 years.
Results: Inclusion of HPV vaccination at age 12 in the cervical cancer prevention program was predicted to be
cost-effective. The incremental cost-effectiveness ratio (ICER) of adding HPV vaccination to the current national
cancer screening program was estimated to be 27 588 $/QALY. The results were sensitive to the price of the
vaccine, the discount rate, the screening participation rate and whether herd immunity was taken into account.
Conclusions: Our modeling analysis showed that the vaccination of 12-year-old adolescent girls against cervical
cancer with the AS04-adjuvanted human papillomavirus 16/18 vaccine would be a cost-effective strategy to
prevent cervical cancer in Hungary.
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Since the introduction of human papillomavirus (HPV)
vaccines, both primary and secondary preventive (i.e.,
screening) measures have been available to prevent cervical
cancer. Health policy makers need to answer the following
question: what is the most effective and cost-effective strat-
egy for cervical cancer prevention in a certain country?
Although there is insufficient evidence regarding the
effectiveness of cervical screening (Pap-smear) among
vaccinated women [1], most policy recommendations* Correspondence: vokoz@t-online.hu
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reproduction in any medium, provided the oradvocate continuation of the screening programs in vac-
cinated women because current vaccines do not provide
protection against all oncogenic types of HPV and be-
cause the overall vaccine efficacy against cervical cancer
is less than 100% [2-4].
Thus, the relevant question from the health policy per-
spective is whether introducing a cervical cancer vaccin-
ation program for adolescents in parallel with the
screening program is cost-effective.
The organized cervical screening program was
launched for women aged 25–65 in 2003 as part of the
National Public Health Program in Hungary aiming to
target those women who otherwise would not use the
service. Unfortunately, the organized screening program
had only a small positive effect on the percentage of thed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Improving the effectiveness of the cervical cancer pre-
vention program is on the agenda of Hungarian health
policy makers. We have recently developed a health eco-
nomic model to study the cost-effectiveness of different
possible screening strategies [7].
In addition to the development of the current screen-
ing program, policy makers need to decide whether to
introduce vaccination against cervical cancer. The vac-
cination of adolescent girls is the most likely form of
vaccination to be added to the program. There are two
vaccines available for preventing cervical cancer. One of
these is CervarixTM, an AS04-adjuvanted bivalent vaccine
against HPV types 16 and 18 produced by GlaxoSmithKline.
The second vaccine, Gardasil TM, is active against HPV
types 6, 11, 16 and 18. The purpose of this study was to
assess the cost-effectiveness of adding vaccination with
the AS04-adjuvanted human papillomavirus 16/18 vaccine
(CervarixTM) at age 12 to the current national cervical
screening program. We have not considered screening
methods other then the prevailing one in the national cer-
vical cancer screening program.
Methods
We developed a cohort simulation state-transition Mar-
kov-model using Microsoft Excel software. The model
estimates the life course of 12-year-old girls.
The disease progression part of the cost-effectiveness
model was based on a previously published model (Figure 1)
[7-9]. The boxes represent health states, and the arrows
represent transition routes between the health states. We
calculated the transition probabilities for a cycle length of
one month assuming a constant incidence rate for one
cycle (see these incidences in Additional file 1). The time
horizon of the model was 88 years, i.e., the accumulated









Figure 1 Health states used in the disease progression model. CIN: ceData on quality-of-life (QoL) weights were taken from a
previously published Hungarian model assessing the cost-
effectiveness of different screening strategies (Table 1) [7].
The discount rates of cost and quality of life years
(QALY) are user inputs in the model. For the base case,
we used 3.7% for both discount rates, which is in line
with the recommendation of the working group on dis-
count rates in health economic analysis lead by the Na-
tional Health Fund. We also provide the results
calculated with a discount rate of 5%, which is specified
in the current Hungarian guidelines for health economic
evaluations [10]. Our analysis was conducted from the
public health care payer’s perspective.Screening
An organized cervical cancer screening program was
launched for women aged 25 to 65 years in 2003 as part
of the National Public Health Program. Women were
invited to undergo cervical screening every 3 years. The
method of screening followed the longstanding Hungar-
ian professional tradition of opportunistic screening; it
included Papanicolaou test and colposcopic examination
performed by gynecologists in outpatient services
located in cities. Regarding the procedures following the
screening test, if a person has a Papanicolaou 3 (P3) cy-
tology result, she receives a combination of local anti-
inflammatory treatment and the cytology is repeated
within 2 weeks. If the subsequent result is P3 or worse
again, then conization is offered just like for those who
had a P4 or P5 result initially. If the subsequent result
after an initial P3 cytology is P2, then the cytology is
repeated again in 6 months. If this result is Papanicolaou
1 (P1) or Papanicolaou 2 (P2), then the patient returns
to the regular screening regimen. If the result is worse












rvical intraepithelial neoplasia, CC: cancer, HPV: human papilloma virus.
Table 1 Quality of life weights* corresponding to
different cancer stages
Non-detected Newly detected Treated
CC I-IIA 1.0 (0.1000) 0.68 (0.0680) 0.95 (0.0950)
CC IIB-III 0.95 (0.0950) 0.56 (0.0560) 0.75 (0.0750)
CC IV 0.9 (0.0900) 0.48 (0.0480) 0.60 (0.0600)
The numbers in brackets are the standard errors applied for the distributions
in the probabilistic sensitivity analysis.
*The age specific quality of life weights are multiplied with these weights.
Table 3 The default setting of the distribution of the
screening test results according to the disease stages
Stage
Test result Normal CIN 1 CIN 2,3 CC I CC II-IV
P1-2 0.31 0.1 0.04 0.01 0
P3 0.621 0.45 0.48 0.04 0
P4-5 0.069 0.45 0.48 0.95 1
CIN: cervical intraepithelial neoplasia, CC: cancer, P: Papanicolaou.
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assumed to occur every 3 years in the model. The pro-
portion of women starting and stopping cervical screen-
ing can be set in the model at each screening period,
allowing great flexibility of modeling different uptakes of
screening at different ages. In the default setting, we set
the proportion of women starting and stopping screen-
ing at each round of the screening in such a way that
the participation rates were in line with the current age-
specific participation rate figures (Table 2) [11]. The data
on the test characteristics of the combined test of cytolo-
gic and colposcopic examinations were taken from our
model for cervical screening (Table 3) [7].
Vaccination
Three different vaccination strategies can be modeled:
no vaccination, vaccination at age 12 with lifetime pro-
tection assumed, and vaccination at age 12 plus boosterTable 2 Proportion of the population screened within
three years by age group




















>69 0%vaccination 20 years later assuming a waning of the vac-
cine efficacy after 20 years.
The efficacy of vaccination was modeled as the prod-
uct of the proportion of cervical cancers caused by the
oncogenic HPV types that the vaccine provides protec-
tion against and the vaccine efficacy against a 6-month
persistent infection with these types of HPV. For the
former, 71.5% was used as the default value because that
is the proportion of cervical cancers that can be attribu-
ted to HPV types 16 and 18 in Europe [12]. The vaccine
efficacy against persistent HPV 16/18 infection was
modeled as 94.3% [13]. We took into account cross-
protection against other types of HPV in the sensitivity
analysis of the model because the vaccine provides sig-
nificant protection not only for HPV types 16 and 18
but also for HPV types 33, 31 and 45 (Table 4) [14]. Al-
though the model did not directly distinguish the differ-
ent high risk HPV types, this way we could model the
efficacy considering different HPV types. Additionally,
we performed sensitivity analysis with the intention-to-
treat estimate of the efficacy parameter, which was 90.2%
in all vaccinated subjects who had received at least one
dose, for whom data concerning efficacy endpoint mea-
sures were available and who had a normal or low-grade
cytology (defined as negative, or ASCUS or LSIL) at
month 0 [13]. The incidence among vaccinated persons
was assumed to be decreased by the vaccine efficacy.
Current evidence suggests long-term vaccine efficacy
[14,15]. Mathematical modeling predicts that the AS04-
adjuvanted HPV 16/18 vaccine provides long-lastingTable 4 Cervical cancers attributable to different types of
HPV and protection against 6-month persistent infections
by the AS04-adjuvanted bivalent vaccine
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[16,17]. Based on the current evidence, we did not as-
sume waning immunity in the base; nevertheless, in the
sensitivity analysis, we assessed the cost-effectiveness as-
suming that the vaccine efficacy decreases to 50% from
20 to 30 years after vaccination and a booster is given
20 years after the first immunization in 80% of women
vaccinated at the age of 12.
Vaccination coverage can be set for both the initial
vaccination and for the booster dose as a percentage of
the cohort; the base case values were 80% for the former
and 0% for the latter. Vaccination coverage had rele-
vance if herd immunity was taken into account. Herd
immunity was modeled by applying an additional reduc-
tion in the incidence rate from state “No CIN, HPV
negative” to the state “No CIN, HPV positive”. The inci-
dence rate applied was inversely related to the vaccin-
ation coverage rate and the vaccine efficacy. The
incidence rate in the population was estimated as the
weighted average of the expected incidence among non-
vaccinated and vaccinated persons, where the weights
were the proportions of these subpopulations. Herd im-
munity was taken into account in the base case scenario.
If the vaccination coverage did not reach 30%, the model
did not take into account the herd immunity effect.
For the base case, no decrease in the quality of life due
to the vaccination was assumed.
Cost data
The cost of the screening process and cancer treatment
was taken from a previously published model (Table 5)
[7]. The nominal prices paid by the National Sick Fund
for the units of in- and outpatient services have
increased by 2.74% since the cost estimation was per-
formed for the previous model. Therefore, we updated
the cost data accordingly. The initial model included
costs in Hungarian forints. These costs were converted
to US$ based on the purchasing power parity exchange
rate of 129 HUF/$ (2010) to eliminate differences in
price levels between countries [18]. Resource utilization
data of the screening process was estimated per proto-
col: resource units were multiplied by the tariffs of theTable 5 Direct medical cost ($) per month of cervical
cancer by stages and time after the diagnosis
Time after the diagnosis
Stage Months 0-3 Months 4-12 Months 13-24 From
month 25
CC I-IIa 1 157 (289.20) 216 (54.05) 158 (39.39) 99 (24.72)
CC IIb-III 1 157 (289.20) 353 (88.51) 339 (84.54) 283 (70.56)
CC IV 1 157 (289.20) 352 (87.90) 447 (111.82) 328 (81.98)
The numbers in brackets are the standard errors applied for the distributions
in the probabilistic sensitivity analysis.
CC: cancer.National Health Insurance Fund for the services. The
costs of the Pap-smear (National Health Insurance Fund
(NHIF) procedure code: 14720), the cytological examin-
ation (NHIF procedure code: 42700) and of the
gynecological screening examination (NHIF procedure
code 16631 plus 42600) were $0.73, $12.7 and $12,12,
respectively. The price of local anti-inflammatory treat-
ment was $6.24. The cost of the conisation was $1,495.2.
The cost of conisation was calculated by the cost of the
diagnosis-related group “operation of uterus and
adnexum of uterus due to in situ carcinoma and non-
malignant disease” coded as 643B.
We used the European Economic Area’s lowest official
public price of the vaccine, $131.08, in the analysis be-
cause if the vaccination is included in the national vac-
cination scheme in Hungary as a 100% reimbursed
vaccine, then its price cannot be higher than that be-
cause of reference pricing rules. Three doses of the vac-
cine are required for the basic immunization.
We did not consider indirect costs in the analysis.
Sensitivity analysis
We tested the robustness of the results to 10% increases
and decreases in the input parameters. In the probabilis-
tic sensitivity analysis, we defined distributions for the
key input parameters and ran 5000 Monte-Carlo simula-
tions with sampling from these distributions. Gamma
distributions were applied to the incidence rates of tran-
sitions, the participation rates, the cancer stage-specific
mortality, the stage-specific health care costs and the
organizational costs of screening. Ten percent of the
point estimates was used as standard error of the para-
meters. Beta distributions were applied to the screening
participation rates and the quality-of-life weights of the
cancer states. Twenty-five percent of the point estimates
was used as standard error of the parameters. Dirichlet
distribution was used for the sensitivity and specificity of
the screening test. We did not use standard errors for
the parameters with Dirichlet distribution. We plotted
the results on an incremental cost-effectiveness ratio
scatter plot and on an acceptability curve to determine
the proportion of the simulated results that were below
the cost-effectiveness threshold.
Results
Table 6 shows the costs and the QALYs corresponding
to the vaccination and no-vaccination strategies. The in-
cremental cost-effectiveness ratio of vaccination was 27
588 $/QALY. Table 7 shows that the cost-effectiveness
of vaccination was very sensitive to some of the key in-
put parameters, including the price of the vaccine, the
discount rate and whether herd immunity was taken into
account. Without herd immunity, the ICER changed
from 27 588 to 42 520 $/QALY. With the use of the
Table 6 Estimated cost-effectiveness of the different
strategies
Strategy QALY Cost ($) ICER ($/QALY)
no vaccination 22.427 3 348.8 reference
vaccination 22.437 3 629.2 27 588
QALY: quality-adjusted life years, ICER: incremental cost-effectiveness ratio.
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slightly increased to 28 662 $/QALY. When cross-
protection was taken into account, the ICER decreased
to 25 190 $/QALY. Assuming that the vaccine efficacy
waned after 20 years, requiring the administration of a
booster dose, largely decreases the cost-effectiveness.
The results of the detailed deterministic and the prob-
abilistic sensitivity analyses are presented in the online
Additional file 2.
Discussion
Our study aimed to provide health economic data to in-
form the development of the Hungarian cervical cancer
prevention program. First, the national program needs
to address the problem of the inefficiency of the current
screening program [5,6]. We have previously developed
a health economic model to support this decision mak-
ing process [7]. Furthermore, with the introduction of
vaccination against cervical cancer, a new policy ques-
tion was raised: whether to include the vaccination of
adolescent girls in the cervical cancer prevention pro-
gram. We aimed to analyze this question from a health
economic perspective.
Our modeling results predicted that adding vaccin-
ation of adolescent girls with the AS04-adjuvanted
human papillomavirus 16/18 vaccine to the national cer-
vical cancer screening program would be cost-effective
in Hungary. Although our results were quite robust toTable 7 The effect of major input parameters on the
estimated cost-effectiveness of adding vaccination to
screening
ΔQALY Δcost ($) ICER ($/QALY)
base case 0.01016 280.396 27 588
no herd immunity 0.00857 364.382 42 520
with intention-to-treat
efficacy parameter
0.00982 281.534 28 662
with cross-protection 0.01102 277.560 25 190
50% waning of efficacy
from 20 to 30 years after
vaccination and booster
dose in 80% of persons
immunized at age 12 years
and alive after 20 years
0.00728 332.731 45 709
discount rate 5% 0.00532 295.598 55 617
price of the vaccine 231$* 0.01016 520.210 51 184
*current recommended market price of the Cervarix vaccine in Hungary.
QALY: quality-adjusted life years, ICER: incremental cost-effectiveness ratio.the uncertainty in the input parameters, larger changes
in the most influential parameters could considerably
change the result.
An important question from the policy perspective is
whether a catch-up vaccination for older girls/women
would be beneficial and cost-effective. Studying this
question was outside the scope of our analysis because
catch-up vaccination against cervical cancer is not under
consideration in the Hungarian health policy agenda.
Our analysis can be considered a conservative one be-
cause we did not consider potential health benefits of
vaccination other than preventing cervical cancer, in-
cluding protection against other diseases. This lack of
consideration of other potential benefits is true for the
screening test as well. Some gynecological abnormalities
can be detected when the cervical smear is taken. Fur-
thermore, we did not include indirect costs in our ana-
lysis. Another limitation of our study is that the reported
cost-effectiveness can be expected only after a few years
time because it is necessary for the incidence of HPV
among the partners of an actually vaccinated population
to decrease for herd immunity to develop. Furthermore,
we did not use a dynamic transmission model, and did
not model the incidence of the different HPY types.
Therefore, our method of modeling the effect of the
herd immunity can be considered a simple tool to pro-
ject the main features of the potential impact of HPV
vaccines at the population level. Additionally, our model
was somewhat undercalibrated in the young age groups,
and it was well calibrated only above age 44 years, i.e.
the number of the estimated new cases with the current
screening practice and no vaccination was consistent
with the actual incident cases registered in the National
Cancer Registry above age 44 years [7].
Many modeling studies have been published that
investigated the cost-utility of adding HPV vaccination
to existing screening programs in different countries
[19-36]. The direct comparison of the results is not pos-
sible, because of the differences in the methods and be-
cause of the differences in the input parameters. The
studies themselves and their reviews highlighted the lim-
itations of the transferability of health economic evalua-
tions [37-42]. Most of the variations can be explained by
the differences in the model structures (e.g., modeling
herd immunity or not) and in the influential input para-
meters (e.g., the incidence of cervical cancer related to
the effectiveness of the screening, the cost of the vac-
cine, waning of the vaccine efficacy, the use of booster
vaccination, and the value of the discount rate). The
huge effect of the discount rate on these published
results and on our results highlights the challenges
involved in the health economic analysis of primary pre-
ventive programs. In these programs, the return of an
early investment can be expected in the long run in the
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affects the cost, but it devalues the benefit.
A cost-effectiveness analysis of the quadrivalent (6/11/
16/18) HPV vaccine in Hungary has already been pub-
lished [43]. The authors reported that the incremental
cost-effectiveness ratio of adding vaccination at age
12 years to the current screening program was 9 577
€/QALY, which is equivalent to $18 901 when using the
€/HUF exchange rate given the authors used and the pur-
chasing power parity exchange rate of 129 HUF/$. In
addition to the differences between the vaccines studied,
the major methodological differences between studies
make it difficult to compare our results with those of that
analysis. First, our model tracks a cohort, whereas the
other model follows a population of fixed size at any time
point. Hence, the compositions of the numerators and
denominators used in the ICERs differ between the mod-
els. Second, the results of the other study accounted for
the additional benefits conferred by protecting against
HPV 6/11 infection. Finally, the states that were modeled
and the parameters applied differed as well.
Conclusions
Our model predicted that adding vaccination of 12-year-
old adolescent girls with the AS04-adjuvanted human
papillomavirus 16/18 vaccination to the national cervical
screening program would be a cost-effective strategy to
prevent cervical cancer in Hungary.
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